Fingerprint
Dive into the research topics of 'A first-in-human phase 1 study of LY3023414, an Oral PI3K/mTOR dual inhibitor, in patients with advanced cancer'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
A first-in-human phase 1 study of LY3023414, an Oral PI3K/mTOR dual inhibitor, in patients with advanced cancer
Johanna C. Bendell, Anna M. Varghese, David M. Hyman, Todd M. Bauer, Shubham Pant, Sophie Callies, Ji Lin, Ricardo Martinez, Enaksha Wickremsinhe, Aaron Fink, Volker Wacheck, Kathleen N. Moore
Research output: Contribution to journal › Article › peer-review
74
Scopus
citations